Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vepdegestrant + PF-07220060 in ER-positive/HER2-negative advanced or metastatic breast cancer
2023-508130-33-00Phase 2Authorised
- Sponsor
- Pfizer
- Start
- Jul 2024
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of vepdegestrant and atirmociclib in breast cancer (2 arms), sponsored by Pfizer. Primary endpoints: Dose-limiting toxicities and Confirmed objective response. Planned start Jul 2024; status: authorised.
02
Drugs
vepdegestrantatirmociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-508130-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508130-33-00.